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Sleep is an indispensable normal physiology of the human body fundamental for healthy
functioning. It has been observed that Parkinson’s disease (PD) not only exhibits motor
symptoms, but also non-motor symptoms such as metabolic irregularities, altered
olfaction, cardiovascular dysfunction, gastrointestinal complications and especially sleep
disorders which is the focus of this review. A good understanding and knowledge of
the different brain structures involved and how they function in the development of
sleep disorders should be well comprehended in order to treat and alleviate these
symptoms and enhance quality of life for PD patients. Therefore it is vital that the normal
functioning of the body in relation to sleep is well understood before proceeding on to
the pathophysiology of PD correlating to its symptoms. Suitable treatment can then
be administered toward enhancing the quality of life of these patients, perhaps even
discovering the cause for this disease.
Keywords: sleep, Parkinson’s disease (PD), suprachiasmatic nucleus (SCN), non-rapid eye movement sleep
(NREMS), rapid eye movement sleep (REMS), dopamine, hypocretin, REMS behavior disorder (RBD)
INTRODUCTION
Sleep is vital to foster adequate health and bodily function (Altevogt and Colten, 2006) as it is
an active physiological process needed to protect and normalize all major organs and regulatory
systems (Altevogt and Colten, 2006; Barbara and Philips, 2006). Cellular function in the brain is
altered radically during sleep (Maquet et al., 1997). Steadfast patterns of the aroused brain are
substituted by low-frequency synchronization and fluctuating neuronal rhythms are displayed
on the electroencephalogram (EEG; Niedermeyer and Lopes da Silva, 2005). The elementary
mechanism of sleep is known as the sleep-wake cycle, which is controlled through homeostatic sleep
drive (Process S) and circadian arousal drive (Process C; Altevogt and Colten, 2006; Barbara and
Philips, 2006; NCBI Bookshelf, 2006; Moore, 2007). Process S induces sleep through its proposed
regulator adenosine. Increasing wakefulness periods results in increased adenosine which increases
the need for sleep (Barbara and Philips, 2006). Contrariwise, during sleep, levels of adenosine
decrease, thus reducing the need for sleep. Circadian rhythms induce sleep through cyclical changes
in the 24 h daily rhythms of physiology and behavior in an individual, which is regulated through
the biological clock in humans (Barbara and Philips, 2006; NCBI Bookshelf, 2006). This biological
clock consists of a pair of cluster neurons in the anterior ventral hypothalamus above the optic
chiasm of the brain, known as the suprachiasmatic nucleus (SCN; see Figure 1).
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Parkinson’s disease (PD) is portrayed by a classical triad of
movement disorders comprising bradykinesia, worsening resting
tremors and rigidity with impaired postural reflexes (Williams-
Gray et al., 2007). However, established non-motor symptoms
also occur which lead to cognitive decline progressing onto
dementia (Williams-Gray et al., 2007; Pontone et al., 2013). These
include metabolic irregularities, altered olfaction, cardiovascular
dysfunction, gastrointestinal complications, and, especially
addressed in this review, sleep disorders and disturbances (Park
and Stacy, 2009; Chaudhuri and Odin, 2010; Claassen et al.,
2010; Menza et al., 2010; Ziemssen and Reichmann, 2010). An
interesting aspect is that manifestation precedes decades before
the onset of motor symptoms (Willison et al., 2013).
PD is thought to be caused by dopaminergic neuronal
degeneration in the SN pars compacta (Garcia-Borreguero et al.,
2003), which occurs due to Lewy body disease. This results in
abnormal accumulations of α-synuclein in neurons. Obvious
indicators are exhibited when sufficient nigral degeneration
leads to the onset of motor symptoms (Boeve, 2013). However,
it has become more illuminating as a multisystem disorder
where numerous other brain structures are progressively affected
as the disease advances (Jellinger, 2010; Jain, 2011; Willison
et al., 2013). This is seen in the impaired functioning of
the extrapyramidal system, which consequently damage arousal
mechanisms (Arnulf, 2005) and thus ensues in sleep disorders.
SLEEP-WAKE REGULATION
Sleep-wake regulation is coordinated through the interchange of
Process S and C (Moore, 2007), where process C functions to
establish sleep and wake into discrete periods. Wakefulness is
initiated and maintained through an activated cerebral cortex
via two factors, where both arise from input from multiple
activating systems. This is via mechanisms of the ascending
reticular activating system (ARAS), and the resistance of Process
S by Process C (Moore, 2007).
The ARAS from the brainstem activating the cerebral
forebrain structures involves two major pathways. The first
pathway includes projections from serotonin (SE) neurons of
the dorsal raphe nuclei (DRN), noradrenaline or norepinephrine
(NE) neurons of the locus coeruleus (LC), and dopamine (DA)
neurons of the substantia nigra (SN) and ventral tegmental
area (VTA). These neurons innervate the entire forebrain. The
second pathway include projections from glutamate, hypocretin,
and the histaminergic tuberomammillary nucleus (TMN) of the
posterior hypothalamus, midline-intralaminar thalamus, and the
Abbreviations: Electroencephalogram, EEG; Suprachiasmatic nucleus, SCN;
serotonin, SE; dorsal raphe nuclei, DRN; norepinephrine, NE; ventral tegmental
area, VTA; locus coeruleus, LC; pedunculopontine nucleus, PPN; non-rapid
eye movement sleep, NREMS; rapid eye movement sleep, REMS; slow wave
sleep, SWS; ventrolateral pre-optic nucleus, VLPO; gamma-aminobutyric acid,
GABA; laterodorsal tegmental nucleus, LDT; sublateordorsal tegmental nucleus,
SLD; ventrolateral periaqueductal gray, vlPAG; monoamine oxidase, MAO;
autonomic nervous system, ANS; excessive daytime sleepiness, EDS; REMS
behavior disorder; restless legs syndrome, RLS; periodic limb movements, PLM;
REMS without atonia, RWA; magnocellular reticular formation, MCRF; sleep
apnea syndrome, SAS.
cholinergic nucleus basalis neurons which innervate via the
diencephalic and basal forebrain to the cortex (Moore, 2007; see
Figure 2).
In PD, damage and cell loss occur in the dopaminergic
VTA, serotonergic DRN, noradrenergic LC and vagus nerve
dorsal nucleus cell, cholinergic Meynert basal nucleus, neocortex,
hippocampus, Edinger Westpal and pedunculopontine nucleus
(PPN), peptidergic neuropeptide Y neurons in the spinal
cord, somatostatic hippocampus and cortex, substance P in
the medulla, and the cholecystokinic and metenkephalic basal
ganglia (Garcia-Borreguero et al., 2003; Arnulf, 2005). Significant
reduction of hypocretin (Hcrt) is especially observed in the lateral
cerebral ventricle of patients with severe PD (Arnulf, 2005).
SLEEP ARCHITECTURE IN HEALTHY
ADULTS
Sleep is divided into non-rapid eye movement sleep (NREMS),
and rapid eye movement sleep (REMS; Walker, 2005) which
alternate intermittently throughout the night (Altevogt and
Colten, 2006; Barbara and Philips, 2006; Carskadon and Dement,
2011). NREMS is further divided into 4 stages (Walker, 2005),
where stages 3 and 4 are collectively known as Slow Wave Sleep
(SWS; Barbara and Philips, 2006).
A healthy adult falls asleep within 10 min and undergo a cyclic
sequence of the five sleep stages, beginning with NREMS stage
1 advancing onto stage 2, followed by SWS and finally REMS.
The individual then resumes back to NREMS (Carskadon and
Dement, 2011), and the cycle recommences.
REMS and NREMS substitute throughout the night in an
ultradian pattern every 85–100 min consisting of 3–5 cycles each
night (Fry, 1985), where NREMS dictates the first half of the night
mostly with SWS, whereas REMS and stage 2 NREMS abound in
the latter half of the night (Walker, 2005).
The Sleep-Wake Cycle
Entry into NREMS stage 1 occurs when the circadian drive for
arousal diminishes and Process S takes over Process C, where
optimal adenosine levels are reached.
Studies show that increases in adenosine or adenosine A1
receptor agonists in the rat basal forebrain and cat ventrolateral
pre-optic nucleus (VLPO), promote sleep through inhibition of
multiple wake-promoting brain areas and excitation of sleep-
promoting cell groups (Scammell et al., 2000; Strecker et al.,
2000). Adenosine also excites VLPO neurons by disinhibiting
gamma-aminobutyric acid (GABA) inputs (Chamberlin et al.,
2003). Thus, through inhibition of the basal forebrain arousal
system and triggering of the VLPO nucleus, adenosine acts as a
homeostatic regulator for sleep need, and induces sleep (Schwartz
and Roth, 2008). Comprised of GABA and galanin (Gal), VLPO
neurons inhibit arousal systems and set the thalamocortical
network into a progressive state of synchronization, initiated by
synchronous discharge of the thalamic reticular nucleus. This
promotes sleep spindle generation and the initiation of stage 1
NREMS (Steriade, 2003; Llinás and Steriade, 2006; McCarley,
2007). The mechanism between activation of the VLPO and
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FIGURE 1 | The Suprachiasmatic Nucleus (Adapted and published under the Creative Commons Attribution-Share Alike 3.0 Unported license).
FIGURE 2 | The ARAS: VLPO, ventrolateral pre-optic nucleus; PeF, perifornical area; ORX, orexin; TMN, tuberomamillary nucleus; SN, substantia nigra;
VTA, ventral tegmental area; DRN, dorsal raphe nuclei; SE, serotonin; LDT, laterodorsal tegmental nucleus; vlPAG, ventrolateral periaqueductal gray;
PPN, pedunculopontine nucleus; LC, locus coeruleus; NE, norepinephrine. Green lines depict the first pathway, and pink lines depict the second pathway.
(Adapted and published under the Creative Commons Attribution-Share Alike 3.0 Unported license).
deactivation of the arousal systems is known as the flip-flop
switch, which works to alter behavioral states between sleep and
wake (see Figure 3).
Entry into stage 2 NREMS occurs when the thalamus begins
generating and propagating sleep spindles (Schabus et al., 2007),
which lead to the formation of k-complexes (Steriade, 2003).
These measurements are generated from neuronal activity in the
thalamic reticular nucleus, propagating through thalamic relay
nuclei that traverse to the thalamocortical projecting nuclei in
the cerebral cortex (de Andrés et al., 2011). Sleep spindles occur
due to the frequency of these intermediate hyperpolarization
through the interactions of GABA-activated thalamocortical and
reticular thalamic nucleus neurons (McCarley and Chokroverty,
1994). K-complex waves (Izac and Eeg, 2006) occur when there is
sudden increasing amplitude in these sleep spindles (Carskadon
and Dement, 2011).
SWS initiates when brain activity decreases due to decline in
cellular firing in most regions of the brain (J, 1995). This includes
Frontiers in Aging Neuroscience | www.frontiersin.org 3 May 2016 | Volume 8 | Article 114
French and Muthusamy Sleep and Parkinson’s Disease
FIGURE 3 | Model depicting reciprocal interactions between sleep and wake promoting structures in the brain: VLPO, ventrolateral pre-optic nucleus;
eVLPO, extended VLPO; ORX, orexin; TMN, tuberomamillay nucleus; LC, locus coeruleus; DRN, dorsal raphe nuclei, PPN, pedunculopontine nucleus;
LDT, laterodorsal tegmental nucleus; SLD, sublaterodorsal nucleus; Gal, galanine; GABA, gamma-aminobutyric acid; NE, norepinephrine; SE,
serotonin; His, histamine, Glu, glutamate. (Saper et al., 2001).
the forebrain which involves the association and motor cortex,
the thalamic lateral geniculate nucleus and brainstem reticular
formation, the DRN, and the LC. Decreases are also seen in the
dorsal pons and basal ganglia (Maquet et al., 1997), reflecting
significant deactivation of afferent thalamic nuclei and frontal
cortical areas (Maquet et al., 1997). Exhibits of slow delta waves
interspersed with smaller, faster waves are shown on the EEG (J,
1995). Activity decreases observed within the dorsal pons and
mesencephalon reflects the persistent decrease in the firing rate
of neurons of ascending brainstem systems. This leads to the
hyperpolarization of the thalamic nuclei (Steriade and McCarley,
1990) which instantaneously generates SWS slow oscillations.
However, increased firing is observed in portions of the amygdala
and the hypothalamus. Since SWS displays decreased activity
in the thalamocortical system and increased activity in portions
of the limbic system, it is postulated to provide a rest period
for skeletal muscles and optimize activity for the housekeeping
systems of the internal body physiology (J, 1995).
Entry into REMS is shown on the EEG when intense
brain activity shows either tonic activity, which is depicted by
episodic bursts of rapid horizontal eye movements (Walker,
2005), or phasic activity, which is depicted by relative quiescence
(Carskadon and Dement, 2011). REMS is generated by structures
located in the lateral pontine region in the brainstem which
performs as a command and control center (Siegel, 2000). It
was originally proposed that REM-on and -off cellular activity
governing REMS were cholinergic neurons. Activation of the
reticular formation neurons would occur in a positive-feedback
system and termination is induced through the inhibitory activity
of REM-off aminergic neurons through REM-on activated
neuronal modulation located within the laterodorsal tegmental
nucleus (LDT) and PPN regions. Cholinergic activation of the
cortex by the PPN then projects to the thalamocortical pathway
to suppress slow delta waves and induce cortical arousal (Belaid
et al., 2014). However, studies in rats show that brainstem
glutamatergic and GABAergic neurons play a bigger role in
producing and regulating REMS, particularly through REMS-
on glutamatergic neurons located in the pontine sublaterodorsal
tegmental nucleus (SLD). This is due to observations of a
permanent glutamatergic input from the lateral and ventrolateral
periaqueductal gray (vlPAG), and the removal of GABAergic
inhibition at REMS onset which is present during wake and
SWS. Nevertheless this does not preclude the role of cholinergic
neurons in REMS regulation.
REMS onset occurs when glutamatergic REMS-on neurons
from the SLD are activated (Boissard et al., 2002). During
wake and SWS, these REMS-on neurons are inhibited by
a tonic inhibitory GABAergic tone derived from REMS-off
neurons confined in the vlPAG and the dorsal deep mesenphalic
reticular nucleus (Crochet et al., 2006). These neurons are
activated during wake by hypocrtinergic and monoaminergic
neurons (McGinty and Sterman, 1968). REMS onset is gated
by activation of intrinsic mechanisms of REMS-on GABAergic
neurons found in the dorsal paragigantocellular reticular
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nucleus and vlPAG (Gaus et al., 2002) as these neurons
also inactivate the REMS-off monoaminergic neurons during
REMS. The disinhibited ascending SLD PS-on neurons in
turn induce cortical activation via projections to intralaminar
thalamic relay neurons in collaboration with wake and REMS-
on cholinergic and glutamatergic neurons from the LDT and
PPN, the mesencephalic and pontine reticular nuclei, and the
basal forebrain (Luppi et al., 2012). Descending REMS-on
SLD neurons induce muscle atonia and sensory inhibition via
excitatory projections to glycinergic pre-motoneurons localized
in the alpha and ventral gigantocellular nuclei (McGinty and
Sterman, 1968). Exit from REMS occurs when there is activation
of the wake systems as REMS episodes are almost always
terminated by an arousal. The wake systems then inhibit
GABAergic REMS-on neurons localized in the DPGi and vlPAG
(Figure 4).
Arousal occurs when the inhibitory interactions of sleep-
promoting VLPO neurons and the NE, SE, and Ach neurons are
down-regulated by the arousal systems which are blocked by the
VLPO itself during sleep (Gallopin et al., 2000).
The Circadian System and the SCN
The circadian system consists of a network of central and
peripheral oscillators throughout the brain and body, with its
central clock located in the SCN (Willison et al., 2013). It is
a component of the central autonomic network that controls
autonomic functions in a state-dependent manner (Suzuki
et al., 2011). The SCN modulates circadian oscillations in body
systems such as body temperature, endocrine functions, blood
pressure, sleep, and etc., through autonomous rhythms (Ropper,
2009).
Neurons within the SCN receives light information from
melanopsin-expressing retinal ganglion cells from the retina
through the retinohypothalamic tract (RHT), where axons
make direct synaptic connection with SCN cells. This photic
information is assimilated with other timing cues to generate
vigorous circadian oscillations synchronized to the environment,
thus acting as amechanism that entrains the circadian sleep-wake
rhythm to the light-dark cycle of the natural environment (see
Figure 5).
Clock genes interact with each other to generate oscillations of
gene expression, where successive gene activation is modulated
in the form of a cycle. The initial activation of a gene is regulated
by the last one in the sequence, making up an auto-regulatory
feedback loop for which one cycle takes about 24 h. Positive
components activate the expression of negative components,
which reciprocally inhibit the activity of positive components.
This system shifts the normal equilibrium and hence, continuous
cycling results. The circadian clock mechanism consists of
two interconnecting, regulatory feedback loops. The first loop
regulates the transcription of Period (Per) and Cryptochrome
(Cry 1,2). Two transcriptional activators, Bmal1 and Clock, form
heterodimers in the cytoplasm and enter the nucleus where
they bind to E-box sequences in the promoters of Per and
Cry genes (Gekakis et al., 1998; Travnickova-Bendova et al.,
2002; Etchegaray et al., 2003). This augments the expression
activation of Per and Cry proteins which then interact with each
FIGURE 4 | Network model depicting REMS onset: DPGi, dorsal
paragigantocellular reticular nucleus; dDpMe, dorsal deep
mesenphalic reticular nucleus; DRN, dorsal raphe nucleus; GiV, ventral
gigantocellular reticular nucleus; Hcrt, (orexin)-containing neurons;
LC, locus coeruleus; vlPAG, ventrolateral periaqueductal gray; SLD,
sublaterodorsal nucleus.
other, enter the nucleus and inhibit the activity of Bmal1/Clock
complexes (Kume et al., 1999; Sato et al., 2006). This sustains
transcription activation levels of the Per and Cry genes. Thus
Per and Cry genes shut off their own transcription when
their activation levels decline (Ko and Takahashi, 2006). The
second loop regulates the expression of the Bmal1 gene. In
the nucleus Bmal1/Clock heterodimers bind to E-boxes in the
promoters of genes that encode the retinoic acid-related orphan
nuclear receptors, namely Rev-erb! And Ror!. These genes
compete for the ROR element (RORE) in the Bmal1 promoter.
Ror! activates Bmal1 expression, while Rev-erb! suppresses it.
As a consequence oscillations of Bmal1 and Ror!/Rev-erb!are
imbalanced. If activation overpowers expression, Bmal1 protein
is produced and it forms heterodimers in the cytoplasm with
Clock (Preitner et al., 2002). These heterodimers then enter the
nucleus and initiate the next cycle of gene activation of both loops
(see Figure 6).
Transport of clock proteins from the cytoplasm into the
nucleus as well as posttranscriptional processes enhances
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FIGURE 5 | The Retino-Hypothalamo-Pineal (RHP) Pathway (depicted by pink dotted lines): The retinohypothalamic tract (RHT) (green dotted line) is
the first segment of the RHP pathway, which connects the eye to the hypothalamus. Photons activate melanopsin-expressing retinal ganglion cells (mRGC)
which project through the optic nerve to 2nd order neurons in the SCN. SCN neurons then project to 3rd order neurons in the paraventricular nucleus (PVN) of the
hypothalamus. These neurons further project to 4th order preganglionic sympathetic neurons in intermediolateral zone of the thoracic lateral horns of the spinal cord.
These neurons then project to 5th order postganglionic neurons in the superior cervical ganglia, which then project to 6th order cells (pinealocytes) in the pineal gland,
thus making the neurohormone melatonin (Adapted and published under the Creative Commons Attribution-Share Alike 3.0 Unported license).
regulation of the clock mechanism for generating oscillations
of ∼24 h (Harms et al., 2004). Interactions between Per and
Cry proteins prevent rapid self-degradation and enables them
to enter the nucleus. Interaction site mutation in either Per or
Cry protein disturbs the nuclear and cytoplasmic localization
with consequences on the clock oscillator (Ko and Takahashi,
2006). In the generation of mammalian circadian rhythms,
phosphorylation and de-phosphorylation of Per proteins plays a
critical role in determination of period length. The enzyme casein
kinase 1ε or δ (CK1 ε/δ) phosphorylates Per2 protein at different
sites. Thus mutations in the CK1ε as well as in sites of Per2 that
are important for CK1ε binding and phosphorylation can cause
alterations in period length (Lowrey et al., 2000).
DA is also an intermediary of light as it signals to
the retinal circadian clock and provides direct input to the
SCN (Witkovsky, 2004). Through dopaminergic amacrine cells
in the retina, circadian rhythms are conveyed across core
component clock genes of the molecular clock, including Per,
Cry, Clock, and Bmal1. These genes help in tissue adaptation
to environmental illumination to produce optimal photic
response (Dorenbos et al., 2007). By utilizing dopaminergic
D4 receptors, DA moderates rhythms in retinal second
messengers like cAMP through direct interaction with retinal
physiology and sensitivity (Jackson et al., 2011). DA also
affects the phase and amplitude of specific clock genes
through dopaminergic D1 receptors in the retina (Ruan et al.,
2008).
Supplementary visual information is sent to the SCN by
projections from the lateral geniculate nucleus, which is the
thalamic relay for the primary visual system. The SCN then
transmits signals to the hypothalamus, brain stem, pineal gland,
and pituitary to facilitate the activity of sleep-wake systems of the
brainstem as a primary circadian sleep-wake and bodily rhythm
pacemaker (J, 1995).
SCN outputs massively innervate other hypothalamic
regions, including the subparaventricular zone and other medial
hypothalamic structures surrounding it. These hypothalamic
relay nuclei innervate nervous and endocrine systems, where
the SCN output transfers temporal information about the
environment to the rest of the brain and body through
multiple routes. Signals from the SCN also travel out via the
hypothalamic-pituitary adrenal axis and the autonomic nervous
system (ANS) to regulate independent circadian oscillators
throughout the body (Dibner et al., 2010; Mohawk et al., 2012).
The SCN modulates major subcortical arousal centers
including the LC and DRN which increase firing rate during the
wake period (Aston-Jones et al., 2001; Deurveilher and Semba,
2005). Outputs from physiological systems that receive circadian
regulation send feedback to modify and control SCN neural
activity in vivo (Yamazaki et al., 1998; Schaap and Meijer, 2001;
Deboer et al., 2003).
Another major feedback to the SCN is via the pineal gland,
which regulates melatonin production and secretion through
melatonin receptors located at a major site of the SCN.Melatonin
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FIGURE 6 | Flip-flop switch model of sleep-wake regulation between VLPO sleep-promoting and arousal structures neurons (Saper et al., 2005).
is produced at high levels at night and low levels during the day,
controlled by SCN projections to the autonomic subdivision of
the paraventricular nucleus of the hypothalamus. The onset of
sympathetic melatonin production and release inhibits firing of
SCN neurons, which decreases SCN neuronal firing rate during
late day andweakening the circadian drive (Process C) for arousal
(Moore, 2007). This initiates Process S and the sleep-wake cycle.
Circadian Rhythm Dysfunction in PD
The SCN is intact in PD patients however it functions through
innervation with the hypothalamus and brainstem-associated
central autonomic network.
The presence of defective pathways lead to malfunctioning
effects (Willison et al., 2013), which lead to alterations in
circadian rhythmicity. This reduces night-time sleep quality,
daytime alertness and cognitive performance (Buysse et al., 2005).
In PD, a lack of time-dependent variation in Bmal1 expression
in patients compared with controls were found (Breen et al.,
2014). Patients were found to have abnormal sleep macro-
architecture including increased sleep latency, reduced sleep
efficiency, and reduced REMS. This is associated with certain
circulating hormone profiles linked to peripheral clock gene
expression differences. Such evidence suggests that sleep-wake
disturbances in early PD reflects disorder in the neural circuitry
controlling circadian rhythms. It is known that the hypothalamus
is also affected in PD (Langston and Forno, 1978; Politis et al.,
2008), which can lead to a decline in SCN activity responsible
for reduced melatonin output and sleep-wake disruption (Wu
and Swaab, 2005; Nakamura et al., 2011). Also, it was shown
that mice overexpressing α-synuclein demonstrate reduced SCN
firing rate, thus weakening the ability to communicate neural
and hormonal signals from the central clock (Kudo et al., 2011).
PD patients also showed a sustained elevation of serum cortisol
levels and reduced circulating melatonin levels compared with
elderly controls, similar to previous studies (Hartmann et al.,
1997; Bordet et al., 2003).
A possible explanation for this is due to dysregulation
in Bmal1 gene expression. Dopamine regulates Bmal1/ Clock
heterodimer activity (Dibner et al., 2010), thus DA deficiency
can directly affect this central component of the molecular
clock. Striatal dopamine metabolism is apparently regulated by
clock proteins such as Per2 (Hampp et al., 2008). Stimulation
of dopamine receptors also affects the rhythm of clock gene
expressions of Per1 and Per2 in the striatum (Imbesi et al., 2009;
Hood et al., 2010). DA also regulates the rhythmic expression
of melanopsin in retinal ganglion cells, thus influencing the
entrainment of the circadian rhythm by light (Sakamoto et al.,
2005). Considering that DA plays such a crucial role even in
the circadian process of sleep, it should be highly plausible that
the interconnecting relationships of different brain structures
associated with the generation of sleep, including the SCN,
can lead to different kinds of sleep disorders indefinitely.
Alternatively, damage and degeneration to the SCN itself
could be responsible for clock gene dysregulation, or even
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the hypothalamus. Whether circadian disruption in PD can be
linked to the pathophysiology of other circadian sleep disorders
such as advanced sleep phase syndrome (ASPS), delayed sleep
phase syndrome (DSPS), non-24-h sleep wake syndrome, and
seasonal affective disorder, poses a question as some of these
disorders exhibit some of the symptoms seen in sleep disorders
related to PD. Further research will be needed to know the
exact mechanisms behind the occurrence of these disorders
(Cermakian and Boivin, 2003).
The altered timing of physiological rhythms cause internal
desynchronization, leading to loss of rhythm coordination
which cause negative effects on rest-activity cycles and other
physiological and behavioral functions (Reinberg and Ashkenazi,
2008). Circadian fluctuations also occur due to impaired retinal
DA (Wirz-Justice et al., 1984).
Centrally, DA levels are modulated by monoamine oxidase
A (MAO-A) and monoamine oxidase B (MAO-B). MAO-A is a
clock-controlled gene (Hampp et al., 2008), thus disruption of the
circadian clockwork due to loss of DA levels is expected to alter
via MAO-A activity. Loss of DA neurons in PD therefore lead to
circadian disruption as it alters sleep latency and desynchronizes
diurnal rhythm changes (Willison et al., 2013).
Blood pressure, heart rate, cortisol and melatonin hormone
levels are also altered due to autonomic dysfunction, and further
lead to changes in sleep structure (Suzuki et al., 2011). The ANS
is subject to circadian regulation, providing a balance between
sympathetic and parasympathetic tone varying in synchrony with
the daily circadian cycle (Jain and Goldstein, 2012). In healthy
individuals, parasympathetic tone dominates during sleep to
reduce heart rate and blood pressure through mechanics of the
central circadian clock in the SCN via projections to the pre-
autonomic neurons in the paraventricular nucleus (Buijs et al.,
2003). The circadian regulation of the ANS is disrupted in PD
patients, driving changes in blood pressure and heart rate (Kallio
et al., 2000), thus changing sleep structure.
Anti-parkinsonian drugs also affect circadian rhythms and
sleep-wake regulating systems either through direct action on
sleep-wake regulating systems and circadian rhythm generators,
or through indirect action meant to reduce PD symptoms during
sleep (Garcia-Borreguero et al., 2003). It was found that the pineal
gland undergoes compensatory up-regulation of monoaminergic
transmitter systems outside of the basal ganglia, specifically in its
uptake of L-DOPA, the pre-cursor of DA (Ghaemi et al., 2001).
This was shown in a study conducted by Ghaemi et al. (2001)
using the analog F-DOPA. The main factor contributing to this is
long-term medication of L-DOPA, dopamine agonists or MAO-
B inhibitors (Fowler et al., 1994). These drugs influence normal
physiologic DOPA metabolism mechanisms of the pineal gland,
which ultimately result in up-regulation of L-DOPA uptake.
This is via up-regulation of the binding site of striatal DA
uptake carriers found not only in the dopaminergic system,
but adrenergic and serotonergic systems as well (Wiener et al.,
1989). Thus dysregulation of pineal gland function not only arises
from metabolism impairments in the dopaminergic systems,
but from the adrenergic and serotonergic systems as well. This
consequently leads to circadian rhythm dysfunction as the pineal
gland is involved in melatonin synthesis which regulates the
sleep-wake rhythm. Other evidence was found in a study which
showed a nocturnal melatonin peak in PD patients undergoing
treatment with L-DOPA which transpired earlier compared to de
novo patients and healthy controls (Fertl et al., 1993).
Sleep Architecture in PD
PD patients experience reduced total sleep time and sleep
efficiency, increased number of awakenings, and increased
wakefulness after sleep onset (Wetter et al., 2000). Sleep
fragmentation is the most consistent sleep disturbance,
characterized by frequent awakenings and being awake 30–40%
of sleep time. Some studies show a reduction in sleep spindles,
SWS (Garcia-Borreguero et al., 2003), and REMS latency (Kendel
et al., 1972; Poewe and Högl, 2000), whereas increased arousals
lead to excessive daytime sleepiness (EDS). These symptoms
reflect changes in the temporal pattern of sleep due to circadian
dysfunction (Abbott et al., 2005; Dhawan et al., 2006; Reid and
Zee, 2009; Mayer et al., 2011; Schulte and Winkelmann, 2011).
Circadian disruption is thus a critical factor contributing to
insomnia and hypersomnia in PD patients (Mohawk et al.,
2012; Willison et al., 2013). PD patients also experience REMS
behavior disorder (RBD) as structural impairments occur in
the brainstem due to dopaminergic loss and pathway defects,
which is the main region of the brain modulating REMS. Table 1
summarizes the different sleep disorders experienced in patients
with PD. It shows the causes of each disorder and the structures
affected, as well as its effect and symptoms.
SLEEP DISORDERS IN PARKINSON’S
DISEASE
Excessive Daytime Sleepiness (EDS)
EDS is a disabling trend of rapid sleep onset without prior
drowsiness in various circumstances (Frucht et al., 1999) It is a
marker of dopamine loss and the first consequence of dopamine
deficiency prodromal to PD (Arnulf et al., 2002). It is associated
with severe PD, PD-related disability, cognitive decline, frequent
hallucinations, dementia and extended drug therapy including
antihistamines, dopaminergic therapy, anxiolytics and SSRIs
levodopa and dopamine agonist therapy (Dhawan et al., 2006;
Comella, 2007; Belaid et al., 2014).
EDS in PD is mainly due to arousal system damage, especially
owing to selective orexinergic neuronal loss in the posterior
lateral hypothalamus innervating central targets in advanced PD
stages (Arnulf, 2005). This causes a reduction in the number of
A10 dopaminergic neurons in the VTA (Rye, 2004) as orexin
yields Hcrt. This further promotes wakefulness by up-regulating
the mono-aminergic neuronal population. Thus balance is more
in favor of REM-on firing and wakefulness is impaired, which can
lead to narcolepsy (Siegel, 2009; Suzuki et al., 2011).
Supplementary to orexin and histamine systems, impairments
in serotoninergic, noradrenergic, and cholinergic neurons in
the brainstem which serve as arousal systems that maintain
wakefulness also result in EDS (Suzuki et al., 2011).
Dopaminergic drugs are used to ameliorate EDS (España
and Scammell, 2011). DA agonists however have a sedative
effect due to differential selectivity for D1 and D2 receptors.
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TABLE 1 | Summary table of the different sleep disorders in PD, the cause and brain structures affected, and its effect and symptoms.
Sleep disorder
type
Cause Structures affected Effect Symptoms
EDS Arousal system
damage
Orexin neuronal loss in posterior lateral
hypothalamus
VTA
More REM-on firing
Narcolepsy
Sleep onset
Impaired serotonergic (DRN),
noradrenergic (LC) and cholinergic (PPN,
LDT) neurons
Impaired wakefulness
More REM-on firing
Sleep onset
Dopaminergic
drugs
D1/ D2 receptors Sedation Sleep onset
Insomnia Destabilizaition of
the “sleep-
wakefulness”
switch
VLPO hypofunction VLPO neurons remain active
Wake structures fail to
deactivate and sleep onset is
impaired
Prolonged sleep latency
Sleep fragmentation
Difficulty falling and staying asleep
Early awakenings
Over-activity of orexin/ hypocretin system Impaired LC modulation
Gene
dysregulation
Dopaminergic pathway CREB gene up-regulation Sustained wakefulness
Narcolepsy Hypocretin cell
loss
VTA REM-on firing Premature entry into REMS
Hallucinations
Sleep paralysis
Cataplexy
MCH cell loss Hypothalamus REM-on firing
RLS/PLM Circadian rhythm
dysregulation
RLS generator RLS and PLM Delayed sleep onset
Circadian phase
recovery
Neurotransmitter and hormonal fluxes Hypersensitivity Exaggerated hyperalgesia in feet
Neuropathic pain
Dopaminergic
system
dysfunction
A11-diencephalic dopaminergic nucleus
Spinal tract and cord
SCN
Hypothalamus
Impaired sensory suppression
Altered circadian rhythm
regulation
Dysethesia
Melatonin secretion dysregulation Impaired sleep regulation
Dopaminergic
drugs
Sensitivity changes in postsynaptic
dopamine receptors
Impaired dopamine
metabolism
Response changes in prolactin
and growth hormone
RBD Lewy body and
neurite formation
REMS components dysfunction, including:
SLD
MCRF
DRN
Peri-LC (reduced monoaminergic activity)
Locomotor generator changes (inceasing
activity in LDT and PPN)
Mood and behavior changes
RWA
Vivid and frightening dreams
Excessive muscle tone and activity
Complex, dynamic and violent
behaviors
Dream enactment
Dopaminergic
dysfunction
VTA Dysfunction in NRMC and
coeruleus–subcoeruleus
complex
Lesions Ventral midbrain and medial medulla Loss of muscle tone
suppression
Nocturia Dopaminergic
pathway
dysfunction
D1 receptors (under-active)
D2 receptors (over-active)
Detrusor over-activity Frequent and excess urination at
night
(Continued)
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TABLE 1 | Continued
Sleep disorder type Cause Structures affected Effect Symptoms
SCN (Disrupted circadian control) Nocturnal relaxation of bladder
wall
Increased urethral sphincter
tone (abnormal bladder
contraction and urethral
sphincter relaxation)
SAS Nocturnal
akinesia/
dyskinesia of
respiratory muscle
Upper airway muscle dysfunction Vocal cord abductior
dysfunction
Loud crescendo snoring
Irregular snorting
Gasping
Nocturnal stridor
Dopaminergic
durg excess and
withdrawal
(hypersensitive
dopamine
receptors)
Oromandibular/ laryngeal dystonia
Chest wall muscle bradykinesia and rigidity
Respiratory compromise Dyspnea
Tachypnea
Irregular, erratic breathing patterns
D1 agonists and small doses of DA have been shown to
increase firing of orexin neurons in the rat hypothalamus,
while high concentrations of DA and D2 agonists decrease
block this firing (Alberto et al., 2006). Thus patients with
partial orexin deficiency due to low catechol o-methyl-transferase
and monoamine oxidase inhibitors (MAO-I) activity would be
sedated by D2–D3 agonists or high doses of levodopa due to
prolonged action of DA in the synaptic cleft (Arnulf, 2005).
Insomnia
Insomnia exhibits prolonged sleep latency and fragmentation
characterized by difficulty in falling and staying asleep,
early awakening, or non-refreshing sleep despite adequate
opportunities for sleep, coupled with impaired daytime
functioning (Suzuki et al., 2011).
Insomnia occurs when there is a destabilization of the “sleep-
wakefulness switch,” either through altered neurotransmitter
release via medication or by a morphological lesion or
inflammation. This is hypothesized to cause imbalance between
sleep-promoting and arousing brain areas, leading to a
hypofunction of the VLPO and/or an over-activity of the Hcrt
system (Riemann et al., 2010). This results in insomnia as
wake structures fail to deactivate during the transition from
wake to sleep. Up-regulation of the LC and other arousal
strucutres via the orexin/ Hcrt system (Aston-Jones et al., 2001)
leads to insomnia as this promotes arousal due to over-activity
(Figure 7).
Gene dysregulation is also speculated to cause insomnia in
PD. One such gene is CREB, or cAMP-response element binding
protein, where manipulations of CREB conducted through
molecular genetic techniques in mice suggest that CREB is
involved in sustained arousal (Graves et al., 2003). The arousal-
promoting areas, especially the LC, which influences wake-
promoting neuronal groups through the cAMP/PKA/CREB
signaling pathway activation plays a possible role. Reciprocally
after phosphorylation, CREB induces gene expressions that help
sustain wakefulness (Cirelli and Tononi, 2000), and may mediate
cortical arousal in response to NE signals from the LC (Graves
et al., 2003). DA is known to play a role in CREB gene
phosphorylation, and it was shown that loss of dopaminergic
input leads to an oversensitivity of striatal neurons toward DA-
induced CREB phosphorylation than normal (Cole et al., 1994).
Thus it is possible that such a phenomenon leads to CREB gene
up-regulation, which results in gene expressions that sustain
wakefulness. CREB may also mediate cortical arousal in response
to NE signals from the LC, as recent data (Aston-Jones et al.,
2001; Sutcliffe and de Lecea, 2002) suggest that the orexin/ Hcrt
system regulate the activity of the LC (Graves et al., 2003). This
in turn leads to CREB gene up-regulation and thus sustained
wakefulness (Figure 8).
Narcolepsy
Narcolepsy occurs when there is abnormal short delay
and premature entry into REMS, due to disconnections
between REMS components which lead to waking
(Carskadon and Dement, 2011). This results in hypnagogic
hallucinations, sleep paralysis, and most dramatically,
cataplexy.
Pathophysiology is linked to Hcrt neurons carrying
hypothalamic peptides mediating wakefulness via projections
to the VTA, which were almost undetectable in narcoleptic
patients (Chaudhuri and Schapira, 2009). Thannickal et al. also
showed that PD patients endeavor progressive Hcrt cell loss with
advancing disease, along with melanin-concentrating hormone
cell loss throughout the anterior and posterior hypothalamus.
This occurs even before dopaminergic cell loss which result in
motor symptoms. Early loss transpiring before drug treatment
not only explains narcolepsy but also orthostatic hypotension
in PD and abnormal body temperature regulation (Thannickal
et al., 2007) owing to impaired hypothalamic function. As
mentioned above, Hcrt promotes wakefulness by up-regulating
the mono-aminergic neuronal population. As PD patients are
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FIGURE 7 | Flow chart showing relationship between brain structures
governing cortical arousal: CREB (cAMP-response element binding
protein) mediates cortical arousal when prompted by NE signals from
the LC.
observed to have almost complete loss of Hcrt cells, the balance
is more in favor of REM-on firing and thus wakefulness is
impaired, leading to narcolepsy (Siegel, 2009; Suzuki et al., 2011).
It is to be noted that this phenomenon occurs simultaneously
while dysregulation of DA, NE, and SE occur at the same time,
hence further impairing arousal mechanisms and inducing
sleep.
Restless Legs Syndrome (RLS) and
Periodic Limb Movements (PLM)
RLS is manifest by the need to move due to dysethesias in the
limbs that transpire at rest, and is eased by movement. Symptoms
often occur in a circadian pattern, beginning in the day during
periods of rest and becoming more intense in the evening/night
(Baier and Trenkwalder, 2007). The circadian pattern of periodic
limb movements (PLM) that occur almost analogously could be
secondary to the phasic influence of RLS (Lewy, 1999). Sensory
symptoms and PLM during wakefulness further prevent sleep
onset.
Although the central circadian pacemaker does not exhibit
any abnormalities, the severity of symptoms might be indirectly
modulated by an underlying circadian variation. RLS presents
an exacerbation of symptoms at night, supporting the factor of
circadian oscillation. In a study conducted to address circadian
symptom modulation, it was found that circadian oscillation of
FIGURE 8 | Key brain structures affected by Lewy bodies, Lewy
neuritis, and neuronal loss n Parkinson’s disease (highlighted in red
box): SN, substantia nigra; DRN, dorsal raphe nuclei; vlPAG,
ventrolateral periaqueductal gray; LDT, laterodorsal tegmental
nucleus; PPN, pedunculopontine nucleus; LC, locus coeruleus; SLD,
sublaterodorsal nucleus; MCRF, magnocellular reticular formation.
(Adapted and published under the Creative Commons Attribution-Share Alike
3.0 Unported license).
motor and sensorial symptoms can be observed under conditions
of sleep deprivation as well. This suggests homeostatic sleep drive
as an additional factor modulating RLS symptoms. Observations
of RLS seen to be most intense late in the circadian period, and
least intense several hours later early in the following circadian
period suggests the presence of a generator for RLS. PLM is
also observed to occur simultaneously, suggesting the circadian
pattern of PLM to be secondary to phasic influence from the RLS
generator (Lewy, 1999).
Exaggerated hyperalgesia in the feet, (Baier and Trenkwalder,
2007), and neuropathic pain were also shown to be worse in the
evening and night (Odrcich et al., 2006). This evidences that both
circadian phase and recovery following nocturnal sleep play a role
in pain sensitization, thus postulating that endogenous fluxes in
neurotransmitters and hormones succeeding circadian phases are
involved in these variations (Baier and Trenkwalder, 2007).
The pathophysiology of brain structures involved have not
been studied extensively, however animal (Perlow et al., 1977;
Schade et al., 1995) and human studies (Sowers and Vlachakis,
1984; Doran et al., 1990) advocate the existence of circadian
variations in dopaminergic activity (Andretic and Hirsh, 2000;
Nir et al., 2000). Human data show a distinct circadian variation,
with a pattern characterized by an increase in the morning and a
nadir in the late evening/night (Winkelman, 2006). Furthermore,
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circadian variation in the DA system also influences melatonin
secretion, thus affecting sleep regulation. However, the circadian
patternmight not be generated by the dopaminergic system itself,
but by other factors that indirectly modulate it.
RLS secondary to PD has demonstrated that both these
diseases can be treated by specific dopaminergic medications
where both diseases exist (Winkelman, 2006; Möller et al., 2010).
Thus dopaminergic system dysfunction in RLS pathophysiology
is most probably caused by impaired central dopaminergic
transmission (Trenkwalder and Paulus, 2004; Winkelman, 2006),
which is also the cause for PD symptoms. Pathophysiology
is linked to the A11-diencepalic dopaminergic nucleus which
provides the main descending dopaminergic control of the spinal
tract (Qu et al., 2006), serving as a relay to the spinal cord due to
close anatomical relationship with the SCN in the hypothalamus
(Abrahamson and Moore, 2001) involved in circadian rhythm
regulation. A11 cell bodies also project into the dorsal horns
and intermediolateral tracts of the spinal cord (Björklund and
Skagerberg, 1979; Albanese et al., 1985), which are involved in
sensory suppression (Trenkwalder and Paulus, 2004). Therefore,
dopaminergic dysfunction in this area might contribute to the
sensory symptoms of RLS.
Neuroendocrine responses to dopaminergic drugs also
contribute to the cause of RLS. Response changes in prolactin
and growth hormone release after L-dopa administration were
observed at night but not during the day in RLS patients. This
indicates a consequence of circadian changes in the sensitivity
of postsynaptic dopamine receptors at night (Garcia-Borreguero
et al., 2004), exhibiting impaired dopamine metabolism (Baier
and Trenkwalder, 2007). Thus it is suggestive that there is an
increase in the amplitude of circadian variation of dopaminergic
function in patients with RLS compared to healthy controls.
REMS Behavior Disorder (RBD)
RBD is characterized by vivid and frightening dreams or
nightmares, associated with muscle activity that leads to dream
enactment (Comella, 2007). EEG measurements confirm muscle
activity due to lack of atonia, also known as REMS without
atonia or RWA (Boeve et al., 2007). Patients experience drastic
reductions in REMS, decreased sleep efficiency, and increased
sleep fragmentation due to increased stage transitions and
awakenings (Belaid et al., 2014). Abnormal periods of REMs
also occur most often before the onset of REMS. Complex,
dynamic, and violent behaviors due to dream enactment result
in injuries in patients and their bed partners. Polysomnographic
measurements also display excessive chin muscle tone and limb
jerking during REMS (Comella, 2007).
RBD occurs when there is dysfunction in the SLD,
magnocellular reticular formation (MCRF), and peri-LC
structures, which further lead to RWA. Further degeneration of
these structures, together with changes in locomotor generator
structures, lead to obvious RBD. This chronological sequence
of pathology explains why RBD precedes motor symptoms,
cognitive decline and dementia in most patients who develop
PD. In the Braak stage 2 description of PD, it is stated that further
Lewy body and neurite formation in the structures involved in
stage 1 appear, which are the dorsal motor nucleus of the vagus
nerve, olfactory bulb and anterior olfactory nucleus complex.
Lewy body and neurite formation begin to form in the SLD and
precoeruleus region, the MCRF, the DRN, and LC. Once the
accumulation threshold is reached, changes in mood, behavior,
and sleep start to develop. Measurable changes in serotonin and
noradrenaline might also be present at this stage. Degeneration
in the SLD and precoeruleus region, MCRF, or both lessen the
inhibitory effects on the caudal anterior horn cells, thus leading
to RWA (Boeve, 2013) (Figure 9).
Based on animal studies, it is proposed that the SLD
sends projections to spinal motoneurons through a direct
route that causes active inhibition of skeletal muscle activity
in REMS. The SLD also functions through an indirect
route via the ventrolateral reticulospinal tract to reduce
excitation of the MCRF, thus causing a net reduced inhibition
of spinal motoneurons. Therefore lesions, degeneration and
pharmacological manipulation of the SLD or MCRF can cause
RWA, though not yet sufficient to cause dream enactment
behavior (Boeve et al., 2007). The LC works together with
other midbrain regions located beneath and lateral to the vlPAG
(Suzuki et al., 2011). Due to dysfunction of the subcoeruleus
nucleus controlling muscle atonia during REMS, reduced
excitation of the MCRF and disinhibition of spinal motoneurons
occur either directly or indirectly via other brainstem nuclei
(Boeve et al., 2007).
It was also demonstrated that 2 systems are involved
in normal REMS, where one generates muscle atonia and
another suppresses locomotor activity. Muscle atonia is
caused by active inhibition by the MCRF neurons in the
medulla via the ventrolateral reticulospinal tract synapsing on
spinal motoneurons. These MCRF neurons receive excitatory
effects from the peri-LC region in the pons via the lateral
tegmentoreticular tract. Neurons in the peri-LC region are
thought to inhibit the LDT and cholinergic PPN, which
is interconnected with the substantia nigra, hypothalamus,
thalamus, basal forebrain, and frontal cortex. These pontine
structures act as locomotor generators, and are believed to receive
input from supratentorial structures, especially the forebrain and
thalamus, which ultimately influence spinal motoneurons. Thus
during REMS, phasic oculomotor and locomotor activity such
as REMs and muscle twitches occur, however extravagant motor
activity is directly or indirectly inhibited (Schenck et al., 1993).
Therefore any changes especially to the peri-LC region, PPN,
and LDT can also lead to RBD.
In relation to that, the first human RBD case ever reported
presented a marked reduction in the number of neurons in the
LC and increase in the number of neurons in the PPN and LDT
(Schenck et al., 1996). Hence increased activity in cholinergic
neurons and/or decreased disinhibition of the PPN and LDT
due to reduced monoaminergic activity of the LC results in
RBD. Other studies demonstrate that lesions extending from
the ventral midbrain to the medial medulla also cause RWA as
activation of this system suppresses muscle tone (Schenkel and
Siegel, 1989; Lai and Siegel, 1990; Holmes et al., 1994; Lai et al.,
1999, 2008).
Dopaminergic dysfunction in the VTA has also been
associated with RBD pathophysiology based on anatomic (Rye,
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FIGURE 9 | Key brain structures affected by Lewy bodies, Lewy neuritis, and neuronal loss n Parkinson’s disease (highlighted in red box): SN,
substantia nigra; DRN, dorsal raphe nuclei; vlPAG, ventrolateral periaqueductal gray; LDT, laterodorsal tegmental nucleus; PPN, pedunculopontine
nucleus; LC, locus coeruleus; SLD, sublaterodorsal nucleus; MCRF, magnocellular reticular formation. REMS onset occurs when a certain balance is
reached between REMS-on and off neurons as well as inhibitory and excitatory pathways within the different brain structures. Damage and degeneration to these
brain structures and their relationships lead to RBD. (Adapted and published under the Creative Commons Attribution-Share Alike 3.0 Unported license).
1997), pharmacologic (Fantini et al., 2003), and functional
neuroimaging studies (Albin et al., 2000; Johannes Schwarz
and Noachtar, 2003). This further leads to dysfunction in
the NRMC and coeruleus-subceruleus complex, thus leading
to RBD.
Nocturia
Nocturia is a condition of frequent and excess urination during
the night. Autonomic dysfunction of the bladder leading to
nocturia is a frequent complaint in PD patients, commonly
among men (Cheon et al., 2008). Pathophysiology is linked to
dopaminergic pathways affecting bladder activity as D1 receptors
inhibit micturition reflex while D2 receptors activate it, therefore
under-active D1 and an over-active D2 stimulation may explain
this detrusor over-activity (Chaudhuri and Schapira, 2009).
The SCN also regulates osmotic pressure sensing cells
responsible for nocturnal increase in arginine vasopression
secretion, which subsequently reduces the volume of night-time
urine production (Colwell, 2010; Trudel and Bourque, 2010). It
is assumed that disrupted circadian control due to dopaminergic
pathway dysfunction promotes nocturnal relaxation of the
bladder wall and increased urethral sphincter tone. This leads
to abnormal bladder contraction and relaxation of the urethral
sphincter, thus increasing nocturia and urinary incontinence
(Willison et al., 2013).
Sleep Apnea Syndrome (SAS)
SAS results from a deficit in breathing drive in the brain (central
sleep apnea), or a problem with airflow through breathing
passages, also known as obstructive sleep apnea. As breathing
becomes more difficult or ceases a decrease in blood oxygen level
occurs, which in turn results in awakening to restore breathing.
SAS leads to sleep disordered breathing, and is identified through
a history of loud crescendo snoring and irregular snoring with
snorting and gasping (Mitra andChaudhuri, 2009). As the patient
remains in light sleep, they may be unaware of these awakenings,
which occur numerous times a night. Consequently, the patient
experiences little deep restorative sleep at night which leads to
EDS. Apnea has been found in as many as 50% of patients with
PD. Snoring and apneic episodes may be up to three times more
common in PD (12%) than in the general population.
Upper airway muscle dysfunction caused by nocturnal
akinesia or dyskinesia of the respiratory muscle lead to
development of obstructive sleep apnea, which develops onto
life-threatening nocturnal stridor caused by vocal cord abductor
dysfunction (Suzuki et al., 2011). This occurs due to suppression
of SWS or REMS. Successful treatment of breathing problems
with continuous nocturnal positive airway pressure produces
large rebounds of SWS and REMS (Carskadon and Dement,
2011). Respiratorymuscle dyskinesia occurs due to dopaminergic
medication excess and withdrawal (Garcia-Borreguero et al.,
2003). This results in dyspnea, tachypnea and irregular, erratic
breathing patterns. Levodopa also induces oromandibular (Kato
et al., 2007) or laryngeal dystonia (Onoue et al., 2003), causing
respiratory compromise due to upper airway obstruction. These
respiratory disorders are exhibited during the “on state,” and
decline as medication effects cease. However, a wearing off effect
can also be associated with respiratory complaints, particularly
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in advanced PD patients related to laryngeal dystonia, stridor,
and appearance of chest wall muscle bradykinesia and rigidity
(Hartman, 1988). Other wearing off symptoms compromising
respiration includes shortness of breath which resembles a
panic attack (Vázquez et al., 1993). The pathophysiology of
levodopa-related respiratory problems is not well understood,
but it is very likely associated to denervation hypersensitivity of
dopamine receptors to exogenous dopamine in the peripheral
chemoreceptor neurons (Rice et al., 2002). Dopamine is known
to be involved in both peripheral chemoreceptor and brainstem
respiratory center function as hypoxia increases the synthesis and
release of endogenous dopamine by carotid body glomus cells
(Iturriaga et al., 2009). Thus reduced peripheral chemosensitivity
may explain the reduced ventilatory response to hypoxia in PD
(Serebrovskaya et al., 1998).
CONCLUSION
PD and its symptoms are caused by various dysfunctional
structures compromising many control areas in the brain,
resulting in motor and non-motor abnormalities including
sleep. Good comprehension and knowledge of the various brain
structures involved, their relationship, and their pathophysiology
in the initiation and development of these symptoms will
benefit in administering innovative treatments such as deep
brain stimulation. Further studies focusing on genetics and
biochemistry could also help in finding a possible cause and cure
for this debilitating disease.
AUTHOR CONTRIBUTIONS
Ms IF is the main author who wrote the manuscript in order
to have a broader understanding on the pathophysiology of
Parkinson’s disease, especially in aspects Parkinson’s disease and
various brain structures in relation to sleep. KM was the author
who supervised and helped in the writing of this manuscript.
ACKNOWLEDGMENTS
This review was prepared in accordance with research carried out
under the High Impact Research Grant of University of Malaya
(HIR -UM.C/625/1/HIR- MOHE/CHAN/12).
REFERENCES
Abbott, R. D., Ross, G. W., White, L. R., Tanner, C. M., Masaki, K. H.,
Nelson, J. S., et al. (2005). Excessive daytime sleepiness and subsequent
development of Parkinson disease. Neurology 65, 1442–1446. doi:
10.1212/01.wnl.0000183056.89590.0d
Abrahamson, E. E., and Moore, R. Y. (2001). Suprachiasmatic nucleus in the
mouse: retinal innervation, intrinsic organization and efferent projections.
Brain Res. 916, 172–191. doi: 10.1016/S0006-8993(01)02890-6
Albanese, A., Altavista, M., and Rossi, P. (1985). Organization of central nervous
system dopaminergic pathways. J. Neural Transm. Suppl. 22, 3–17.
Alberto, C. O., Trask, R. B., Quinlan, M. E., and Hirasawa, M. (2006). Bidirectional
dopaminergic modulation of excitatory synaptic transmission in orexin
neurons. J. Neurosci. 26, 10043–10050. doi: 10.1523/JNEUROSCI.1819-06.2006
Albin, R., Koeppe, R., Chervin, R., Consens, F., Wernette, K., Frey, K., et al. (2000).
Decreased striatal dopaminergic innervation in REM sleep behavior disorder.
Neurology 55, 1410–1412. doi: 10.1212/WNL.55.9.1410
Altevogt, B. M., and Colten, H. R. (2006). Sleep Disorders and Sleep Deprivation:
An Unmet Public Health Problem. Washington, DC: National Academies Press.
Andretic, R., and Hirsh, J. (2000). Circadian modulation of dopamine receptor
responsiveness inDrosophilamelanogaster. Proc. Natl. Acad. Sci. 97, 1873–1878.
doi: 10.1073/pnas.97.4.1873
Arnulf, I. (2005). Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev. 9,
185–200. doi: 10.1016/j.smrv.2005.01.001
Arnulf, I., Konofal, E., Merino–Andreu, M., Houeto, J. L., Mesnage, V., Welter,
M. L., et al. (2002). Parkinson’s disease and sleepiness an integral part of PD.
Neurology 58, 1019–1024. doi: 10.1212/WNL.58.7.1019
Aston-Jones, G., Chen, S., Zhu, Y., and Oshinsky, M. L. (2001). A neural circuit for
circadian regulation of arousal. Nat. Neurosci. 4, 732–738. doi: 10.1038/89522
Baier, P. C., and Trenkwalder, C. (2007). Circadian variation in restless legs
syndrome. Sleep Med. 8, 645–650. doi: 10.1016/j.sleep.2006.10.011
Barbara, A., and Philips, R. L. G. (2006). Sleep-Wake Cycle: Its Physiology and
Impact on Health. Washington, DC: National Sleep Foundation.
Belaid, H., Adrien, J., Laffrat, E., Tandé, D., Karachi, C., Grabli, D., et al.
(2014). Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment
and pedunculopontine nucleus lesion. J. Neurosci. 34, 9124–9133. doi:
10.1523/JNEUROSCI.0181-14.2014
Björklund, A., and Skagerberg, G. (1979). Evidence for a major spinal cord
projection from the diencephalic A11 dopamine cell group in the rat using
transmitter-specific fluorescent retrograde tracing. Brain Res. 177, 170–175.
doi: 10.1016/0006-8993(79)90927-2
Boeve, B. F. (2013). Idiopathic REM sleep behaviour disorder in the development
of Parkinson’s disease. Lancet Neurol. 12, 469–482. doi: 10.1016/S1474-
4422(13)70054-1
Boeve, B. F., Silber, M. H., Saper, C. B., Ferman, T. J., Dickson, D. W., Parisi, J. E.,
et al. (2007). Pathophysiology of REM sleep behaviour disorder and relevance
to neurodegenerative disease. Brain 130, 2770–2788. doi: 10.1093/brain/
awm056
Boissard, R., Gervasoni, D., Schmidt, M. H., Barbagli, B., Fort, P., and Luppi,
P. H. (2002). The rat ponto-medullary network responsible for paradoxical
sleep onset and maintenance: a combined microinjection and functional
neuroanatomical study. Eur. J. Neurosci. 16, 1959–1973. doi: 10.1046/j.1460-
9568.2002.02257.x
Bordet, R., Devos, D., Brique, S., Touitou, Y., Guieu, J., Libersa, C., et al. (2003).
Study of circadian melatonin secretion pattern at different stages of Parkinson’s
disease. Clin. Neuropharmacol. 26, 65–72. doi: 10.1097/00002826-200303000-
00005
Breen, D. P., Vuono, R., Nawarathna, U., Fisher, K., Shneerson, J. M., Reddy, A. B.,
et al. (2014). Sleep and circadian rhythm regulation in early Parkinson disease.
JAMA Neurol. 71, 589–595. doi: 10.1001/jamaneurol.2014.65
Buijs, R.M., la Fleur, S. E.,Wortel, J., vanHeyningen, C., Zuiddam, L., Mettenleiter,
T. C., et al. (2003). The suprachiasmatic nucleus balances sympathetic and
parasympathetic output to peripheral organs through separate preautonomic
neurons. J. Comp. Neurol. 464, 36–48. doi: 10.1002/cne.10765
Buysse, D. J., Monk, T. H., Carrier, J., and Begley, A. (2005). Circadian patterns
of sleep, sleepiness, and performance in older and younger adults. Sleep 28,
1365–1376.
Carskadon, M. A., and Dement, W. C. (2011). “Monitoring and staging
human sleep,” in Principles and Practice of Sleep Medicine, 5th Edn., eds
M. H. Kryger, T. Roth, and W. C. Dement (St. Louis: Elsevier Saunders),
16–26.
Cermakian, N., and Boivin, D. B. (2003). A molecular perspective of human
circadian rhythm disorders. Brain Res. Rev. 42, 204–220. doi: 10.1016/S0165-
0173(03)00171-1
Chamberlin, N., Arrigoni, E., Chou, T., Scammell, T., Greene, R., and Saper,
C. (2003). Effects of adenosine on gabaergic synaptic inputs to identified
ventrolateral preoptic neurons.Neuroscience 119, 913–918. doi: 10.1016/S0306-
4522(03)00246-X
Frontiers in Aging Neuroscience | www.frontiersin.org 14 May 2016 | Volume 8 | Article 114
French and Muthusamy Sleep and Parkinson’s Disease
Chaudhuri, K. R., and Odin, P. (2010). The challenge of non-motor symptoms
in Parkinson’s disease. Prog. Brain Res. 184, 325–341. doi: 10.1016/S0079-
6123(10)84017-8
Chaudhuri, K. R., and Schapira, A. H. V. (2009). Non-motor symptoms of
Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet
Neurol. 8, 464–474. doi: 10.1016/S1474-4422(09)70068-7
Cheon, S.-M., Ha, M.-S., Park, M. J., and Kim, J. W. (2008). Nonmotor symptoms
of Parkinson’s disease: prevalence and awareness of patients and families.
Parkinsonism Relat. Disord. 14, 286–290. doi: 10.1016/j.parkreldis.2007.09.002
Cirelli, C., and Tononi, G. (2000). Differential expression of plasticity-related
genes in waking and sleep and their regulation by the noradrenergic system.
J. Neurosci. 20, 9187–9194.
Claassen, D. O., Josephs, K. A., Ahlskog, J. E., Silber, M. H., Tippmann-Peikert,
M., and Boeve, B. F. (2010). REM sleep behavior disorder preceding other
aspects of synucleinopathies by up to half a century. Neurology 75, 494–499.
doi: 10.1212/WNL.0b013e3181ec7fac
Cole, D. G., Kobierski, L. A., Konradi, C., and Hyman, S. E. (1994). 6-
Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-
induced phosphorylation of the cAMP-response element-binding protein
in striatal neurons. Proc. Natl. Acad. Sci. U.S.A. 91, 9631–9635. doi:
10.1073/pnas.91.20.9631
Colwell, C. S. (2010). Preventing dehydration during sleep. Nat. Neurosci. 13,
403–404. doi: 10.1038/nn0410-403
Comella, C. L. (2007). Sleep disorders in Parkinson’s disease: an overview. Mov.
Disord. 22(Suppl. 17), S367–S373. doi: 10.1002/mds.21682
Crochet, S., Onoe, H., and Sakai, K. (2006). A potent non-monoaminergic
paradoxical sleep inhibitory system: a reverse microdialysis and single-
unit recording study. Eur. J. Neurosci. 24, 1404–1412. doi: 10.1111/j.1460-
9568.2006.04995.x
de Andrés, I., Garzón, M., and Reinoso-Suárez, F. (2011). Functional anatomy of
non-REM sleep. Front. Neurol. 2:70. doi: 10.3389/fneur.2011.00070
Deboer, T., Vansteensel, M. J., Détári, L., and Meijer, J. H. (2003). Sleep states alter
activity of suprachiasmatic nucleus neurons. Nat. Neurosci. 6, 1086–1090. doi:
10.1038/nn1122
Deurveilher, S., and Semba, K. (2005). Indirect projections from the
suprachiasmatic nucleus to major arousal-promoting cell groups in rat:
implications for the circadian control of behavioural state. Neuroscience 130,
165–183. doi: 10.1016/j.neuroscience.2004.08.030
Dhawan, V., Healy, D. G., Pal, S., and Chaudhuri, K. R. (2006). Sleep-
related problems of Parkinson’s disease. Age Ageing 35, 220–228. doi:
10.1093/ageing/afj087
Dibner, C., Schibler, U., and Albrecht, U. (2010). The mammalian circadian timing
system: organization and coordination of central and peripheral clocks. Annu.
Rev. Physiol. 72, 517–549. doi: 10.1146/annurev-physiol-021909-135821
Doran, A. R., Labarca, R., Wolkowitz, O. M., Roy, A., Douillet, P., and Pickar, D.
(1990). Circadian variation of plasma homovanillic acid levels is attentuated by
fluphenazine in patients with schizophrenia. Arch. Gen. Psychiatry 47, 558–563.
doi: 10.1001/archpsyc.1990.01810180058009
Dorenbos, R., Contini, M., Hirasawa, H., Gustincich, S., and Raviola, E. (2007).
Expression of circadian clock genes in retinal dopaminergic cells. Vis. Neurosci.
24, 573–580. doi: 10.1017/S0952523807070538
España, R. A., and Scammell, T. E. (2011). Sleep neurobiology from a clinical
perspective. Sleep 34, 845–858. doi: 10.5665/SLEEP.1112
Etchegaray, J.-P., Lee, C., Wade, P. A., and Reppert, S. M. (2003). Rhythmic histone
acetylation underlies transcription in the mammalian circadian clock. Nature
421, 177–182. doi: 10.1038/nature01314
Fantini, M., Gagnon, J.-F., Filipini, D., and Montplaisir, J. (2003). The effects of
pramipexole in REM sleep behavior disorder. Neurology 61, 1418–1420. doi:
10.1212/WNL.61.10.1418
Fertl, E., Auff, E., Doppelbauer, A., andWaldhauser, F. (1993). Circadian secretion
pattern of melatonin in de novo parkinsonian patients: evidence for phase-
shifting properties of l-dopa. J. Neural Transm. Park. Dis. Dement. Sect. 5,
227–234. doi: 10.1007/BF02257677
Fowler, J. S., Volkow, N. D., Logan, J., Wang, G. J., Mac Gregor, R. R.,
Schlyer, D., et al. (1994). Slow recovery of human brain MAO B after L-
Deprenyl (Selegeline) withdrawal. Synapse 18, 86–93. doi: 10.1002/syn.8901
80203
Frucht, S., Rogers, J. D., Greene, P. E., Gordon, M. F., and Fahn, S. (1999).
Falling asleep at the wheel: motor vehicle mishaps in persons taking
pramipexole and ropinirole. Neurology 52, 1908–1908. doi: 10.1212/WNL.52.
9.1908
Fry, J. M. (1985). Sleep disorders.Med. Asp. Hum. Sexual. 19, 104–124.
Gallopin, T., Fort, P., Eggermann, E., Cauli, B., Luppi, P.-H., Rossier, J.,
et al. (2000). Identification of sleep-promoting neurons in vitro. Nature 404,
992–995. doi: 10.1038/35010109
Garcia-Borreguero, D., Larrosa, O., and Bravo, M. (2003). Parkinson’s disease and
sleep. Sleep Med. Rev. 7, 115–129. doi: 10.1053/smrv.2002.0229
Garcia-Borreguero, D., Larrosa, O., Granizo, J. J., de la Llave, Y., andHening,W. A.
(2004). Circadian variation in neuroendocrine response to L-dopa in patients
with restless legs syndrome. Sleep 27, 669–673.
Gaus, S., Strecker, R., Tate, B., Parker, R., and Saper, C. (2002).
Ventrolateral preoptic nucleus contains sleep-active, galaninergic
neurons in multiple mammalian species. Neuroscience 115, 285–294. doi:
10.1016/S0306-4522(02)00308-1
Gekakis, N., Staknis, D., Nguyen, H. B., Davis, F. C., Wilsbacher, L. D., King,
D. P., et al. (1998). Role of the CLOCK protein in the mammalian circadian
mechanism. Science 280, 1564–1569.
Ghaemi, M., Rudolf, J., Hilker, R., Herholz, K., and Heiss, W. D. (2001). Increased
pineal Fdopa uptake is related to severity of Parkinson’s disease–A PET study.
J. Pineal Res. 30, 213–219. doi: 10.1034/j.1600-079X.2001.300404.x
Graves, L. A., Hellman, K., Veasey, S., Blendy, J. A., Pack, A. I., and Abel, T.
(2003). Genetic evidence for a role of CREB in sustained cortical arousal. J.
Neurophysiol. 90, 1152–1159. doi: 10.1152/jn.00882.2002
Hampp, G., Ripperger, J. A., Houben, T., Schmutz, I., Blex, C., Perreau-Lenz,
S., et al. (2008). Regulation of monoamine oxidase A by circadian-clock
components implies clock influence on mood. Curr. Biol. 18, 678–683. doi:
10.1016/j.cub.2008.04.012
Harms, E., Kivimäe, S., Young, M. W., and Saez, L. (2004). Posttranscriptional and
posttranslational regulation of clock genes. J. Biol. Rhythms 19, 361–373. doi:
10.1177/0748730404268111
Hartman, D. (1988). Stridor during dystonia phases of Parkinson’s disease. J.
Neurol. Neurosurg. Psychiatr. 51:161. doi: 10.1136/jnnp.51.1.161
Hartmann, A., Veldhuis, J. D., Deuschle, M., Standhardt, H., and Heuser, I. (1997).
Twenty-four hour cortisol release profiles in patients with Alzheimer’s and
Parkinson’s disease compared to normal controls: ultradian secretory pulsatility
and diurnal variation. Neurobiol. Aging 18, 285–289. doi: 10.1016/S0197-
4580(97)80309-0
Holmes, C. J., Mainville, L. S., and Jones, B. E. (1994). Distribution of cholinergic,
GABAergic and serotonergic neurons in the medial medullary reticular
formation and their projections studied by cytotoxic lesions in the cat.
Neuroscience 62, 1155–1178. doi: 10.1016/0306-4522(94)90351-4
Hood, S., Cassidy, P., Cossette, M.-P., Weigl, Y., Verwey, M., Robinson, B., et al.
(2010). Endogenous dopamine regulates the rhythm of expression of the clock
protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine
receptors. J. Neurosci. 30, 14046–14058. doi: 10.1523/JNEUROSCI.2128-
10.2010
Imbesi, M., Yildiz, S., Arslan, A. D., Sharma, R., Manev, H., and Uz, T. (2009).
Dopamine receptor-mediated regulation of neuronal “clock” gene expression.
Neuroscience 158, 537–544. doi: 10.1016/j.neuroscience.2008.10.044
Iturriaga, R., Alcayaga, J., and Gonzalez, C. (2009). “Neurotransmitters in
carotid body function: the case of dopamine–invited article,” in Arterial
Chemoreceptors, eds C. Gonzalez, C. A. Nurse, and C. Peers (Springer),
137–143. doi: 10.1007/978-90-481-2259-2_16
Izac, M. S. M., and Eeg, T. R. (2006). Basic anatomy and physiology
of sleep. Am. J. Electroneurodiagnostic Technol. 46, 18–38. doi:
10.1080/1086508X.2006.11079555
J, B. (1995). Principles of Behavioral Science. Brown and Benchmark Publishers,
114–145; 384–407.
Jackson, C. R., Chaurasia, S. S., Hwang, C. K., and Michael Iuvone, P. (2011).
Dopamine D4 receptor activation controls circadian timing of the adenylyl
cyclase 1/cyclic AMP signaling system in mouse retina. Eur. J. Neurosci. 34,
57–64. doi: 10.1111/j.1460-9568.2011.07734.x
Jain, S. (2011). Multi-organ autonomic dysfunction in Parkinson disease.
Parkinsonism Relat. Disord. 17, 77–83. doi: 10.1016/j.parkreldis.2010.08.022
Frontiers in Aging Neuroscience | www.frontiersin.org 15 May 2016 | Volume 8 | Article 114
French and Muthusamy Sleep and Parkinson’s Disease
Jain, S., and Goldstein, D. S. (2012). Cardiovascular dysautonomia in Parkinson
disease: from pathophysiology to pathogenesis. Neurobiol. Dis. 46, 572–580.
doi: 10.1016/j.nbd.2011.10.025
Jellinger, K. A. (2010). Critical evaluation of the Braak staging scheme for
Parkinson’s disease. Ann. Neurol. 67, 550–550. doi: 10.1002/ana.21638
Johannes Schwarz, M., and Noachtar, S. (2003). Increased muscle activity during
rapid eye movement sleep correlates with decrease of striatal presynaptic
dopamine transporters. IPT and IBZM SPECT imaging in subclinical and
clinically manifest idiopathic REM sleep behavior disorder, Parkinson’s disease,
and controls. Sleep 26, 507–512.
Kallio, M., Haapaniemi, T., Turkka, J., Suominen, K., Tolonen, U., Sotaniemi, K.,
et al. (2000). Heart rate variability in patients with untreated Parkinson’s
disease. Eur. J. Neurol. 7, 667–672. doi: 10.1046/j.1468-1331.2000.
00127.x
Kato, B., Yamada, K., Horiuchi, M., Hirayama, T., and Hasegawa, Y. (2007).
[Case of Parkinson’s disease presenting with unique dyspneic attacks caused
by oromandibular dystonia and sleep apnea syndrome]. Rinsho shinkeigaku=
Clin. Neurol. 47, 577–580.
Kendel, K., Beck, U.,Wita, C., Hohneck, E., and Zimmermann, H. (1972). Influence
of L-DOPA on Night Sleep in Parkinsonian Patients. Archiv für Psychiatrie und
Nervenkrankheiten. Freiburg.
Ko, C. H., and Takahashi, J. S. (2006). Molecular components of the mammalian
circadian clock. Hum. Mol. Genet. 15, R271–R277. doi: 10.1093/hmg/ddl207
Kudo, T., Loh, D. H., Truong, D., Wu, Y., and Colwell, C. S. (2011). Circadian
dysfunction in a mouse model of Parkinson’s disease. Exp. Neurol. 232, 66–75.
doi: 10.1016/j.expneurol.2011.08.003
Kume, K., Zylka, M. J., Sriram, S., Shearman, L. P., Weaver, D. R., Jin, X., et al.
(1999). mCRY1 and mCRY2 are essential components of the negative limb
of the circadian clock feedback loop. Cell 98, 193–205. doi: 10.1016/S0092-
8674(00)81014-4
Lai, Y. Y., Hsieh, K. C., Nguyen, D., Peever, J., and Siegel, J. M. (2008). Neurotoxic
lesions at the ventral mesopontine junction change sleep time and muscle
activity during sleep: an animal model of motor disorders in sleep.Neuroscience
154, 431–443. doi: 10.1016/j.neuroscience.2008.03.085
Lai, Y. Y., Shalita, T., Hajnik, T., Wu, J. P., Kuo, J. S., Chia, L. G., et al.
(1999). Neurotoxic N-methyl-d-aspartate lesion of the ventral midbrain
and mesopontine junction alters sleep–wake organization. Neuroscience 90,
469–483. doi: 10.1016/S0306-4522(98)00429-1
Lai, Y. Y., and Siegel, J. M. (1990). Cardiovascular and muscle tone changes
produced by microinjection of cholinergic and glutamatergic agonists
in dorsolateral pons and medial medulla. Brain Res. 514, 27–36. doi:
10.1016/0006-8993(90)90432-B
Langston, J. W., and Forno, L. S. (1978). The hypothalamus in Parkinson disease.
Ann. Neurol. 3, 129–133. doi: 10.1002/ana.410030207
Lewy, A. (1999). The dim light melatonin onset, melatonin assays and biological
rhythm research in humans. Neurosignals 8, 79–83. doi: 10.1159/0000
14573
Llinás, R. R., and Steriade, M. (2006). Bursting of thalamic neurons and states of
vigilance. J. Neurophysiol. 95, 3297–3308. doi: 10.1152/jn.00166.2006
Lowrey, P. L., Shimomura, K., Antoch, M. P., Yamazaki, S., Zemenides, P. D.,
Ralph, M. R., et al. (2000). Positional syntenic cloning and functional
characterization of the mammalian circadian mutation tau. Science 288,
483–492. doi: 10.1126/science.288.5465.483
Luppi, P.-H., Clement, O., Sapin, E., Peyron, C., Gervasoni, D., Léger, L., et al.
(2012). Brainstemmechanisms of paradoxical (REM) sleep generation. Pflügers
Arch. 463, 43–52. doi: 10.1007/s00424-011-1054-y
Maquet, P., Degueldre, C., Delfiore, G., Aerts, J., Péters, J.-M., Luxen, A., et al.
(1997). Functional neuroanatomy of human slow wave sleep. J. Neurosci. 17,
2807–2812.
Mayer, G., Jennum, P., Riemann, D., andDauvilliers, Y. (2011). Insomnia in central
neurologic diseases–occurrence andmanagement. SleepMed. Rev. 15, 369–378.
doi: 10.1016/j.smrv.2011.01.005
McCarley, R. W. (2007). Neurobiology of REM and NREM sleep. Sleep Med. 8,
302–330. doi: 10.1016/j.sleep.2007.03.005
McCarley, R. W., and Chokroverty, S. (1994). “Neurophysiology of sleep: Basic
mechanisms underlying control of wakefulness and sleep,” in Sleep Disorders
Medicine; Basic Science, Technical Considerations and Clinical Aspects, ed S.
Chokroverty (Boston, MA: Butterworth-Heinemann), 17–36.
McGinty, D. J., and Sterman, M. B. (1968). Sleep suppression after basal forebrain
lesions in the cat. Science 160, 1253–1255. doi: 10.1126/science.160.3833.
1253
Menza, M., Dobkin, R. D., Marin, H., and Bienfait, K. (2010). Sleep disturbances in
Parkinson’s disease.Mov. Disord. 25, S117–S122. doi: 10.1002/mds.22788
Mitra, T., and Chaudhuri, K. R. (2009). Sleep dysfunction and role of
dysautonomia in Parkinson’s disease. Parkinsonism Relat. Disord. 15, S93–S95.
doi: 10.1016/S1353-8020(09)70790-4
Mohawk, J. A., Green, C. B., and Takahashi, J. S. (2012). Central and peripheral
circadian clocks in mammals. Annu. Rev. Neurosci. 35, 445–462. doi:
10.1146/annurev-neuro-060909-153128
Möller, J. C., Unger, M., Stiasny-Kolster, K., and Oertel, W. H. (2010). Restless Legs
Syndrome (RLS) and Parkinson’s disease (PD)—Related disorders or different
entities? J. Neurol. Sci. 289, 135–137. doi: 10.1016/j.jns.2009.08.035
Moore, R. Y. (2007). Suprachiasmatic nucleus in sleep–wake regulation. SleepMed.
8, 27–33. doi: 10.1016/j.sleep.2007.10.003
Nakamura, T. J., Nakamura, W., Yamazaki, S., Kudo, T., Cutler, T., Colwell,
C. S., et al. (2011). Age-related decline in circadian output. J. Neurosci. 31,
10201–10205. doi: 10.1523/JNEUROSCI0451-11.2011
NCBI Bookshelf (2006). Sleep Physiology - Sleep Disorders and Sleep Deprivation.
NLoM National Institues of Health
Niedermeyer, E., and Lopes da Silva, F. H. (2005). Electroencephalography: Basic
Principles, Clinical Applications, and Related Fields. Philadelphia, PA: Lippincott
Williams &Wilkins.
Nir, I., Haque, R., and Iuvone, P. M. (2000). Diurnal metabolism of dopamine in
themouse retina. Brain Res. 870, 118–125. doi: 10.1016/S0006-8993(00)02409-4
Odrcich, M., Bailey, J. M., Cahill, C. M., and Gilron, I. (2006). Chronobiological
characteristics of painful diabetic neuropathy and postherpetic neuralgia:
diurnal pain variation and effects of analgesic therapy. Pain 120, 207–212. doi:
10.1016/j.pain.2005.10.007
Onoue, H., Yukitake, M., Kurohara, K., Takasima, H., and Kuroda, Y. (2003). [A
case report of Parkinson’s disease presenting with recurrent dyspneic attacks
due to focal laryngeal dystonia].Rinsho shinkeigaku=Clin. Neurol. 43, 192–194.
Park, A., and Stacy, M. (2009). Non-motor symptoms in Parkinson’s disease. J.
Neurol. 256, 293–298. doi: 10.1007/s00415-009-5240-1
Perlow, M., Gordon, E. K., Ebert, M., Hoffman, H., and Chase, T. (1977). The
circadian variation in dopamine metabolism in the subhuman primate. J.
Neurochem. 28, 1381–1383. doi: 10.1111/j.1471-4159.1977.tb12336.x
Poewe, W., and Högl, B. (2000). Parkinson’s disease and sleep. Curr. Opin. Neurol.
13, 423–426. doi: 10.1097/00019052-200008000-00009
Politis, M., Piccini, P., Pavese, N., Koh, S.-B., and Brooks, D. J. (2008). Evidence
of dopamine dysfunction in the hypothalamus of patients with Parkinson’s
disease: an in vivo 11 C-raclopride PET study. Exp. Neurol. 214, 112–116. doi:
10.1016/j.expneurol.2008.07.021
Pontone, G. M., Palanci, J., Williams, J. R., and Bassett, S. S. (2013). Screening
for DSM-IV-TR cognitive disorder NOS in Parkinson’s disease using the
Mattis Dementia Rating Scale. Int. J. Geriatr. Psychiatry 28, 364–371. doi:
10.1002/gps.3833
Preitner, N., Damiola, F., Zakany, J., Duboule, D., Albrecht, U., and Schibler,
U. (2002). The orphan nuclear receptor REV-ERBα controls circadian
transcription within the positive limb of the mammalian circadian oscillator.
Cell 110, 251–260. doi: 10.1016/S0092-8674(02)00825-5
Qu, S., Ondo, W. G., Zhang, X., Xie, W. J., Pan, T. H., and Le, W. D. (2006).
Projections of diencephalic dopamine neurons into the spinal cord in mice.
Exp. Brain Res. 168, 152–156. doi: 10.1007/s00221-005-0075-1
Reid, K. J., and Zee, P. C. (2009). “Circadian rhythm disorders,” in Paper Presented
at the Semin Neurol. (Chicago, IL :Thieme Medical Publishers).
Reinberg, A., and Ashkenazi, I. (2008). Internal desynchronization of circadian
rhythms and tolerance to shift work. Chronobiol. Int. 25, 625–643. doi:
10.1080/07420520802256101
Rice, J., Antic, R., and Thompson, P. D. (2002). Disordered respiration as a
levodopa-induced dyskinesia in Parkinson’s disease.Mov. Disord. 17, 524–527.
doi: 10.1002/mds.10072
Riemann, D., Spiegelhalder, K., Feige, B., Voderholzer, U., Berger, M., Perlis, M.,
et al. (2010). The hyperarousal model of insomnia: a review of the concept and
its evidence. Sleep Med. Rev. 14, 19–31. doi: 10.1016/j.smrv.2009.04.002
Ropper, A. H. (2009).Adams and Victor’s Principles of Neurology, Vol. 9. New York,
NY: McGraw-Hill Medical.
Frontiers in Aging Neuroscience | www.frontiersin.org 16 May 2016 | Volume 8 | Article 114
French and Muthusamy Sleep and Parkinson’s Disease
Ruan, G., Allen, G. C., Yamazaki, S., and McMahon, D. G. (2008). An autonomous
circadian clock in the inner mouse retina regulated by dopamine and GABA.
PLoS Biol. 6:e249. doi: 10.1371/journal.pbio.0060249
Rye, D. B. (1997). Contributions of the pedunculopontine region to normal and
altered REM sleep. J. Sleep Res. Sleep Med. 20, 757–788.
Rye, D. B. (2004). The two faces of eve dopamine’s modulation of wakefulness and
sleep. Neurology 63(8 suppl. 3), S2–S7. doi: 10.1212/wnl.63.8_suppl_3.s2
Sakamoto, K., Liu, C., Kasamatsu, M., Pozdeyev, N. V., Iuvone, P. M., and Tosini,
G. (2005). Dopamine regulates melanopsin mRNA expression in intrinsically
photosensitive retinal ganglion cells. Eur. J. Neurosci. 22, 3129–3136. doi:
10.1111/j.1460-9568.2005.04512.x
Saper, C. B., Chou, T. C., and Scammell, T. E. (2001). The sleep switch:
hypothalamic control of sleep and wakefulness. Trends Neurosci. 24, 726–731.
doi: 10.1016/S0166-2236(00)02002-6
Saper, C. B., Scammell, T. E., and Lu, J. (2005). Hypothalamic regulation of sleep
and circadian rhythms. Nature 437, 1257–1263. doi: 10.1038/nature04284
Sato, T. K., Yamada, R. G., Ukai, H., Baggs, J. E., Miraglia, L. J., Kobayashi, T. J.,
et al. (2006). Feedback repression is required for mammalian circadian clock
function. Nat. Genet. 38, 312–319. doi: 10.1038/ng1745
Scammell, T. E., Estabrooke, I. V., McCarthy, M. T., Chemelli, R. M., Yanagisawa,
M., Miller, M. S., et al. (2000). Hypothalamic arousal regions are activated
during modafinil-induced wakefulness. J. Neurosci. 20, 8620–8628.
Schaap, J., and Meijer, J. H. (2001). Opposing effects of behavioural activity
and light on neurons of the suprachiasmatic nucleus. Eur. J. Neurosci. 13,
1955–1962. doi: 10.1046/j.0953-816x.2001.01561.x
Schabus, M., Dang-Vu, T. T., Albouy, G., Balteau, E., Boly, M., Carrier, J., et al.
(2007). Hemodynamic cerebral correlates of sleep spindles during human non-
rapid eye movement sleep. Proc. Natl. Acad. Sci. U.S.A. 104, 13164–13169. doi:
10.1073/pnas.0703084104
Schade, R., Vick, K., Ott, T., Sohr, R., Pfister, C., Bellach, J., et al. (1995). Circadian
rhythms of dopamine and cholecystokinin in nucleus accumbens and striatum
of rats—influence on dopaminergic stimulation.Chronobiol. Int. 12, 87–99. doi:
10.3109/07420529509064504
Schenck, C. H., Garcia-Rill, E., Skinner, R. D., Anderson, M. L., and Mahowald,
M. W. (1996). A case of REM sleep behavior disorder with autopsy-confirmed
Alzheimer’s disease: postmortem brain stem histochemical analyses. Biol.
Psychiatry 40, 422–425. doi: 10.1016/0006-3223(96)00070-4
Schenck, C. H., Hurwitz, T. D., andMahowald,M.W. (1993). REM sleep behaviour
disorder: an update on a series of 96 patients and a review of the world
literature. J. Sleep Res. 2, 224–231. doi: 10.1111/j.1365-2869.1993.tb00093.x
Schenkel, E., and Siegel, J. M. (1989). REM sleep without atonia after lesions of
the medial medulla. Neurosci. Lett. 98, 159–165. doi: 10.1016/0304-3940(89)
90503-X
Schulte, E. C., andWinkelmann, J. (2011). When Parkinson’s disease patients go to
sleep: specific sleep disturbances related to Parkinson’s disease. J. Neurol. 258,
328–335. doi: 10.1007/s00415-011-5933-0
Schwartz, J. R., and Roth, T. (2008). Neurophysiology of sleep and wakefulness:
basic science and clinical implications. Curr. Neuropharmacol. 6, 367–378. doi:
10.2174/157015908787386050
Serebrovskaya, T., Karaban, I., Mankovskaya, I., Bernardi, L., Passino, C.,
and Appenzeller, O. (1998). Hypoxic ventilatory responses and gas
exchange in patients with Parkinson’s disease. Respiration 65, 28–33. doi:
10.1159/000029224
Siegel, J. M. (2000). Brainstem mechanisms generating REM sleep. Princ. Pract.
Sleep Med. 3, 112–133.
Siegel, J. M. (2009). The Neurobiology of Sleep. Semin. Neurol. 29, 277–296. doi:
10.1055/s-0029-1237118
Sowers, J., and Vlachakis, N. (1984). Circadian variation in plasma dopamine levels
in man. J. Endocrinol. Invest. 7, 341–345. doi: 10.1007/BF03351014
Steriade, M. (2003). The corticothalamic system in sleep. Front. Biosci. 8, d878–
d899. doi: 10.2741/1043
Steriade, M., and McCarley, R. W. (1990). Brainstem Control of Wakefulness and
Sleep, 1990. New York, NY: Plenum Press.
Strecker, R. E., Morairty, S., Thakkar, M. M., Porkka-Heiskanen, T., Basheer, R.,
Dauphin, L. J., et al. (2000). Adenosinergic modulation of basal forebrain and
preoptic/anterior hypothalamic neuronal activity in the control of behavioral
state. Behav. Brain Res. 115, 183–204. doi: 10.1016/S0166-4328(00)00258-8
Sutcliffe, J. G., and de Lecea, L. (2002). The hypocretins: setting the arousal
threshold. Nat. Rev. Neurosci. 3, 339–349. doi: 10.1038/nrn808
Suzuki, K., Miyamoto, M., Miyamoto, T., Iwanami, M., and Hirata, K. (2011).
Sleep Disturbances Associated with Parkinson’s disease. Parkinsons. Dis.
2011:219056. doi: 10.4061/2011/219056
Thannickal, T. C., Lai, Y.-Y., and Siegel, J. M. (2007). Hypocretin (orexin)
cell loss in Parkinson’s disease. Brain 130, 1586–1595. doi: 10.1093/brain/
awm097
Travnickova-Bendova, Z., Cermakian, N., Reppert, S. M., and Sassone-Corsi,
P. (2002). Bimodal regulation of mPeriod promoters by CREB-dependent
signaling and CLOCK/BMAL1 activity. Proc. Natl. Acad. Sci. U.S.A. 99,
7728–7733. doi: 10.1073/pnas.102075599
Trenkwalder, C., and Paulus, W. (2004). Why do restless legs occur at rest?—
pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part
2). Clin. Neurophysiol. 115, 1975–1988. doi: 10.1016/j.clinph.2004.01.031
Trudel, E., and Bourque, C. W. (2010). Central clock excites vasopressin neurons
by waking osmosensory afferents during late sleep. Nat. Neurosci. 13, 467–474.
doi: 10.1038/nn.2503
Vázquez, A., Jimenez-Jimenez, F., Garcia-Ruiz, P., and García-Urra, D. (1993).
“Panic attacks” in Parkinson’s disease. Acta Neurol. Scand. 87, 14–18. doi:
10.1111/j.1600-0404.1993.tb04068.x
Walker, M. P. (2005). A refined model of sleep and the time course of
memory formation. Behav. Brain Sci. 28, 51–64. doi: 10.1017/S0140525X050
00026
Wetter, T. C., Collado-Seidel, V., Pollmächer, T., Yassouridis, A., and Trenkwalder,
C. (2000). Sleep and periodic leg movement patterns in drug-free patients with
Parkinson’s disease and multiple system atrophy. J. Sleep Res. Sleep Med. 23,
361–367.
Wiener, H. L., Hashim, A., Lajtha, A., and Sershen, H. (1989). Chronic L-deprenyl-
induced up-regulation of the dopamine uptake carrier. Eur. J. Pharmacol. 163,
191–194. doi: 10.1016/0014-2999(89)90418-4
Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., and Barker, R.
A. (2007). Evolution of cognitive dysfunction in an incident Parkinson’s disease
cohort. Brain 130, 1787–1798. doi: 10.1093/brain/awm111
Willison, L. D., Kudo, T., Loh, D. H., Kuljis, D., and Colwell, C. S. (2013).
Circadian dysfunction may be a key component of the non-motor symptoms
of Parkinson’s disease: insights from a transgenic mouse model. Exp. Neurol.
243, 57–66. doi: 10.1016/j.expneurol.2013.01.014
Winkelman, J. (2006). Considering the causes of RLS. Eur. J. Neurol. 13, 8–14. doi:
10.1111/j.1468-1331.2006.01586.x
Wirz-Justice, A., Da Prada, M., and Remé, C. (1984). Circadian rhythm in rat
retinal dopamine.Neurosci. Lett. 45, 21–25. doi: 10.1016/0304-3940(84)90323-9
Witkovsky, P. (2004). Dopamine and retinal function. Doc. Ophthalmol. 108,
17–39. doi: 10.1023/B:DOOP.0000019487.88486.0a
Wu, Y. H., and Swaab, D. F. (2005). The human pineal gland and melatonin in
aging and Alzheimer’s disease. J. Pineal Res. 38, 145–152. doi: 10.1111/j.1600-
079X.2004.00196.x
Yamazaki, S., Kerbeshian, M. C., Hocker, C. G., Block, G. D., and Menaker, M.
(1998). Rhythmic properties of the hamster suprachiasmatic nucleus in vivo. J.
Neurosci. 18, 10709–10723.
Ziemssen, T., and Reichmann, H. (2010). Cardiovascular autonomic dysfunction
in Parkinson’s disease. J. Neurol. Sci. 289, 74–80. doi: 10.1016/j.jns.2009.08.031
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 French and Muthusamy. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 17 May 2016 | Volume 8 | Article 114
